COTQF - Cotinga Pharmaceuticals Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.0520
0.0000 (0.00%)
At close: 12:28PM EDT
Stock chart is not supported by your current browser
Previous Close0.0520
Open0.0450
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0520 - 0.0520
52 Week Range0.0121 - 0.2499
Volume13,000
Avg. Volume1,142
Market Cap761,181
Beta (5Y Monthly)5.37
PE Ratio (TTM)N/A
EPS (TTM)-0.1690
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Cotinga Pharmaceuticals Releases Additional Interim Data of Phase 1b/2a Combination Trial of COTI-2 in Solid Tumors
    GlobeNewswire

    Cotinga Pharmaceuticals Releases Additional Interim Data of Phase 1b/2a Combination Trial of COTI-2 in Solid Tumors

    Cotinga Pharmaceuticals Inc. (TSX Venture: COT) (“Cotinga” or the “Company”), a clinical-stage pharmaceutical company advancing a pipeline of targeted therapies for the treatment of cancer, announced today that the Company has released additional interim data of its ongoing Phase 1b/2a clinical trial of COTI-2 plus cisplatin in solid tumors. “We are pleased to continue updating our investment community as we progress the combination trial evaluating COTI-2 plus cisplatin in solid tumors,” said Alison Silva, Cotinga’s President & CEO.

  • Cotinga Pharmaceuticals Announces Initiation of Next Cohort of Phase 1b/2a Combination Trial of COTI-2 in Solid Tumors
    GlobeNewswire

    Cotinga Pharmaceuticals Announces Initiation of Next Cohort of Phase 1b/2a Combination Trial of COTI-2 in Solid Tumors

    Cotinga Pharmaceuticals Inc. (TSX Venture: COT) (“Cotinga” or the “Company”), a clinical-stage pharmaceutical company advancing a pipeline of targeted therapies for the treatment of cancer, announced today that the Company has initiated the third cohort of its ongoing Phase 1b/2a clinical trial of COTI-2 plus cisplatin in solid tumors. The objective of the third cohort is to continue to evaluate the safety and tolerability of COTI-2 in combination with standard-of-care cisplatin.

  • Cotinga Pharmacueticals Announces Closing of Second Tranche of Unit Offering
    GlobeNewswire

    Cotinga Pharmacueticals Announces Closing of Second Tranche of Unit Offering

    Cotinga Pharmaceuticals  Inc. (TSX Venture: COT) (“Cotinga” or the “Company”), a clinical stage biopharmaceutical company advancing a pipeline of targeted therapies for the treatment of cancer, today announced that effective June 4, 2019 (the “Closing Date”), it completed, for gross proceeds of $100,000, a second tranche offering (the “Offering”) of units (“Units”) comprised of $100,000 of senior secured debentures (the “Debentures”) and 1,000,000 non-transferable common share purchase warrants exercisable at $0.10 per Warrant to arm’s length lenders and a lender who is a director and officer of the Company (the “Subscribers”). The Company intends to use the proceeds from the Offering to fund the initiation of both COTI-2 combination trials (one in solid tumors with cisplatin and the other in triple negative breast cancer with eribulin) and for general operations as well as corporate purposes.

  • Cotinga Pharmacueticals Announces Closing of Unit Offering
    GlobeNewswire

    Cotinga Pharmacueticals Announces Closing of Unit Offering

    Cotinga Pharmaceuticals Inc. (TSX Venture: COT) (“Cotinga” or the “Company”), a clinical stage biopharmaceutical company advancing a pipeline of targeted therapies for the treatment of cancer, today announced that effective May 22, 2019 (the “Closing Date”), it completed, for gross proceeds of $199,970, an offering (the “Offering”) of units (“Units”) comprised of $199,970 of senior secured debentures (the “Debentures”) and 1,999,700 non-transferable common share purchase warrants exercisable at $0.10 per Warrant to arm’s length lenders and a lender who is a director of the Company (the “Subscribers”). The Company intends to use the proceeds from the Offering to fund the initiation of both COTI-2 combination trials (one in solid tumors with cisplatin and the other in triple negative breast cancer with eribulin) and for general operations as well as corporate purposes.

  • Cotinga Pharmaceuticals Releases Early Interim Data of Phase 1b/2a Combination Trial of COTI-2 in Solid Tumors
    GlobeNewswire

    Cotinga Pharmaceuticals Releases Early Interim Data of Phase 1b/2a Combination Trial of COTI-2 in Solid Tumors

    Cotinga Pharmaceuticals Inc. (TSX Venture: COT) (“Cotinga” or the “Company”), a clinical-stage pharmaceutical company advancing a pipeline of targeted therapies for the treatment of cancer, announced today that the Company has released early interim data of its ongoing Phase 1b/2a clinical trial of COTI-2 plus cisplatin in solid tumors. The primary objective of the second cohort is to continue to evaluate the safety and tolerability of COTI-2 in combination with standard-of-care cisplatin.  Secondary objectives include determination of efficacy and pharmacokinetics profiling.

  • Cotinga Pharmaceuticals Reports Fiscal 2019 Third Quarter Financial and Operating Results
    GlobeNewswire

    Cotinga Pharmaceuticals Reports Fiscal 2019 Third Quarter Financial and Operating Results

    OTCQB: COTQF) (“Cotinga” or the “Company”), a clinical-stage pharmaceutical company advancing a pipeline of targeted therapies for the treatment of cancer, reported its financial and operating results today for the three and nine months ended January 31, 2019. The Company announced that it has entered into a research partnership with St. Vincent’s University Hospital in Dublin, Ireland with the intent to evaluate COTI-2 in combination with eribulin in patients with triple negative metastatic breast cancer (TNBC).

  • Cotinga Pharmacueticals Provides Scientific and Business Update at Annual General Meeting and Announces Unit Offering
    GlobeNewswire

    Cotinga Pharmacueticals Provides Scientific and Business Update at Annual General Meeting and Announces Unit Offering

    Cotinga Pharmaceuticals  Inc. (TSX Venture: COT) (“Cotinga” or the “Company”), a clinical stage biopharmaceutical company advancing a pipeline of targeted therapies for the treatment of cancer, today announced that its President & Chief Executive Officer, Alison Silva, presented a business and scientific update summarizing recent achievements, upcoming milestones and 2019 objectives at the Company’s Annual General and Special Meeting of Shareholders (“AGM”) held on Tuesday, March 19, 2019. “The end of fiscal 2018 and into 2019 was a period of transition for Cotinga.

  • Cotinga Pharmaceuticals Doses First Patient in Second Cohort of Phase 1b/2a Combination Trial of COTI-2 in Solid Tumors
    GlobeNewswire

    Cotinga Pharmaceuticals Doses First Patient in Second Cohort of Phase 1b/2a Combination Trial of COTI-2 in Solid Tumors

    Cotinga Pharmaceuticals Inc. (TSX Venture: COT) (“Cotinga” or the “Company”), a clinical-stage pharmaceutical company advancing a pipeline of targeted therapies for the treatment of cancer, announced today that the Company has commenced dosing patients in the second cohort of its ongoing Phase 1b/2a clinical trial of COTI-2 plus cisplatin in solid tumors. The objective of the second cohort is to continue to evaluate the safety and tolerability of COTI-2 in combination with standard-of-care cisplatin.

  • Cotinga Pharmaceuticals Doses Cohort 1 Patients With Combination Therapy in Phase 1b/2a Trial of COTI-2
    GlobeNewswire

    Cotinga Pharmaceuticals Doses Cohort 1 Patients With Combination Therapy in Phase 1b/2a Trial of COTI-2

    Cotinga Pharmaceuticals Inc. (TSX Venture: COT) (“Cotinga” or the “Company”), a clinical-stage pharmaceutical company advancing a pipeline of targeted therapies for the treatment of cancer, today announced that it has dosed the first cohort of patient with COTI-2 in combination with standard of care chemotherapy in its ongoing Phase 1b/2a trial. “We are pleased with the progress we have made in dosing of cohort 1 patients in our COTI-2 plus cisplatin combination trial,” said Alison Silva, President and Chief Executive Officer. “The patients in our ongoing Phase 1b/2a trial are suffering from a wide spectrum of cancers with little to no therapeutic options, and we are hopeful that combining existing chemotherapy regimens with COTI-2 could be a potential treatment.

  • Cotinga Pharmaceuticals Doses First Patient With Combination Therapy in Phase 1b/2a Trial of COTI-2
    GlobeNewswire

    Cotinga Pharmaceuticals Doses First Patient With Combination Therapy in Phase 1b/2a Trial of COTI-2

    Cotinga Pharmaceuticals Inc. (TSX Venture: COT) (“Cotinga” or the “Company”), a clinical-stage pharmaceutical company advancing a pipeline of targeted therapies for the treatment of cancer, today announced that it has dosed the first patient with COTI-2 in combination with standard of care chemotherapy in its ongoing Phase 1b/2a trial. Additionally, the first cohort of the trial has been fully enrolled at MD Anderson Cancer Center.

  • Cotinga Pharmaceuticals Enrolls Two Patients for Combination Therapy in Phase 1b/2a Trial of COTI-2
    GlobeNewswire

    Cotinga Pharmaceuticals Enrolls Two Patients for Combination Therapy in Phase 1b/2a Trial of COTI-2

    Cotinga Pharmaceuticals Inc. (TSX Venture: COT) (“Cotinga” or the “Company”), a clinical-stage pharmaceutical company advancing a pipeline of targeted therapies for the treatment of cancer, today announced that it has enrolled two of three patients in the first cohort in its ongoing Phase 1b/2a trial assessing the combination of COTI-2 and cisplatin in solid tumors. “This is an important milestone in the clinical development of our lead asset, and a meaningful step forward in our efforts to evaluate COTI-2 as a combination therapy,” said Alison Silva, President and Chief Executive Officer. “We are encouraged by the enthusiasm of our investigators who have been working diligently to screen and enroll patients for combination therapy.

  • Cotinga Pharmaceuticals Reports Fiscal 2019 Second Quarter Financial and Operating Results
    GlobeNewswire

    Cotinga Pharmaceuticals Reports Fiscal 2019 Second Quarter Financial and Operating Results

    OTCQB: COTQF) (“Cotinga” or the “Company”), a clinical-stage pharmaceutical company advancing a pipeline of targeted therapies for the treatment of cancer, reported its financial and operating results today for the three and six months ended October 31, 2018. Cotinga continued its initiation of the combination therapy trial at MD Anderson Cancer Center evaluating COTI-2 and cisplatin in a wide spectrum of cancers. The Company announced that it has entered into a research collaboration with St. Vincent’s University Hospital in Dublin, Ireland to evaluate COTI-2 in combination with eribulin in patients with triple negative metastatic breast cancer (TNBC).

  • Cotinga Pharmaceuticals Announces Research Partnership with St. Vincent’s University Hospital to Evaluate COTI-2
    GlobeNewswire

    Cotinga Pharmaceuticals Announces Research Partnership with St. Vincent’s University Hospital to Evaluate COTI-2

    OTCQB: COTQF) (“Cotinga” or the “Company”), a clinical-stage pharmaceutical company advancing a pipeline of targeted therapies for the treatment of cancer, today announced that it has entered into a research collaboration with St. Vincent’s University Hospital in Dublin, Ireland to evaluate COTI-2 in combination with eribulin in patients with triple negative metastatic breast cancer. “Cotinga is committed to the development of therapies for a wide range of cancers, and our collaboration with St. Vincent’s University Hospital represents an important step towards realizing the full potential of our lead compound, COTI-2,” said Dr. Richard Ho, M.D., Ph.D., Chief Scientific Officer.

  • When Will Cotinga Pharmaceuticals Inc (CVE:COT) Become Profitable?
    Simply Wall St.

    When Will Cotinga Pharmaceuticals Inc (CVE:COT) Become Profitable?

    Cotinga Pharmaceuticals Inc’s (TSXV:COT): Cotinga Pharmaceuticals Inc., a biopharmaceutical company, develops therapies for the treatment of cancers. With the latest financial year loss of -CA$6.21M and a trailing-twelve month ofRead More...